Your browser doesn't support javascript.
loading
Thrombopoietin mimetic stimulates bone marrow vascular and stromal niches to mitigate acute radiation syndrome.
Vercellino, Justin; Malachowska, Beata; Kulkarni, Shilpa; Bell, Brett I; Shajahan, Shahin; Shinoda, Kosaku; Eichenbaum, Gary; Verma, Amit K; Ghosh, Sanchita P; Yang, Weng-Lang; Frenette, Paul S; Guha, Chandan.
Affiliation
  • Vercellino J; Department of Radiation Oncology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
  • Malachowska B; Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Kulkarni S; Department of Radiation Oncology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
  • Bell BI; Department of Radiation Oncology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
  • Shajahan S; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
  • Shinoda K; Department of Radiation Oncology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
  • Eichenbaum G; Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Verma AK; Department of Radiation Oncology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
  • Ghosh SP; Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Yang WL; Johnson & Johnson, Office of the Chief Medical Officer, New Brunswick, NJ, USA.
  • Frenette PS; Bioconvergent Health, LLC, Purchase, NY, USA.
  • Guha C; Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
Stem Cell Res Ther ; 15(1): 123, 2024 Apr 29.
Article in En | MEDLINE | ID: mdl-38679747
ABSTRACT

BACKGROUND:

Acute radiation syndrome (ARS) manifests after exposure to high doses of radiation in the instances of radiologic accidents or incidents. Facilitating regeneration of the bone marrow (BM), namely the hematopoietic stem and progenitor cells (HSPCs), is key in mitigating ARS and multi-organ failure. JNJ-26366821, a PEGylated thrombopoietin mimetic (TPOm) peptide, has been shown as an effective medical countermeasure (MCM) to treat hematopoietic-ARS (H-ARS) in mice. However, the activity of TPOm on regulating BM vascular and stromal niches to support HSPC regeneration has yet to be elucidated.

METHODS:

C57BL/6J mice (9-14 weeks old) received sublethal or lethal total body irradiation (TBI), a model for H-ARS, by 137Cs or X-rays. At 24 h post-irradiation, mice were subcutaneously injected with a single dose of TPOm (0.3 mg/kg or 1.0 mg/kg) or PBS (vehicle). At homeostasis and on days 4, 7, 10, 14, 18, and 21 post-TBI with and without TPOm treatment, BM was harvested for histology, BM flow cytometry of HSPCs, endothelial (EC) and mesenchymal stromal cells (MSC), and whole-mount confocal microscopy. For survival, irradiated mice were monitored and weighed for 30 days. Lastly, BM triple negative cells (TNC; CD45-, TER-119-, CD31-) were sorted for single-cell RNA-sequencing to examine transcriptomics after TBI with or without TPOm treatment.

RESULTS:

At homeostasis, TPOm expanded the number of circulating platelets and HSPCs, ECs, and MSCs in the BM. Following sublethal TBI, TPOm improved BM architecture and promoted recovery of HSPCs, ECs, and MSCs. Furthermore, TPOm elevated VEGF-C levels in normal and irradiated mice. Following lethal irradiation, mice improved body weight recovery and 30-day survival when treated with TPOm after 137Cs and X-ray exposure. Additionally, TPOm reduced vascular dilation and permeability. Finally, single-cell RNA-seq analysis indicated that TPOm increased the expression of collagens in MSCs to enhance their interaction with other progenitors in BM and upregulated the regeneration pathway in MSCs.

CONCLUSIONS:

TPOm interacts with BM vascular and stromal niches to locally support hematopoietic reconstitution and systemically improve survival in mice after TBI. Therefore, this work warrants the development of TPOm as a potent radiation MCM for the treatment of ARS.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thrombopoietin / Bone Marrow / Acute Radiation Syndrome / Mice, Inbred C57BL Limits: Animals Language: En Journal: Stem Cell Res Ther Year: 2024 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thrombopoietin / Bone Marrow / Acute Radiation Syndrome / Mice, Inbred C57BL Limits: Animals Language: En Journal: Stem Cell Res Ther Year: 2024 Document type: Article Affiliation country: Estados Unidos